BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...primary endpoint of improving PFS over Sutent sunitinib...
...everolimus also improved PFS and ORR over Sutent...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...for the Sutent sunitinib control arm. ORR was also twice as high as that of Sutent...
BioCentury | Apr 28, 2020
Product Development

Blueprint stumbles in GIST race, clearing path for Deciphera

...on the call. Deciphera is conducting the Phase III INTRIGUE trial of ripretinib vs. Sutent sunitinib...
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

...kinase inhibitor Cabometyx met the primary endpoint of significantly extending progression-free survival (PFS) vs. Sutent sunitinib...
...KEYNOTE-426 trial in the same patient setting had a 31% risk reduction on PFS vs. Sutent...
BioCentury | Aug 29, 2019
Clinical News

Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

...Sutent sunitinib from Pfizer Inc. (NYSE:PFE) did not improve 18-month survival, a co-primary endpoint, vs. Sutent...
...combination with Sutent led to complete tumor responses in 11% of patients vs. 4% for Sutent...
BioCentury | Aug 13, 2019
Clinical News

Big gain for Deciphera as GIST readout portends face-off with Blueprint

...HR=0.36; nominal p=0.0004). INVICTUS tested ripretinib in patients who had previously received Gleevec imatinib, Sutent sunitinib...
...3-4 months or more would be "clinically meaningful" in INVICTUS. Data in the labels of Sutent...
...companies therapies' are in other Phase III trials as well. Deciphera is evaluating ripretinib vs. Sutent...
BioCentury | Jun 11, 2019
Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

...INTRIGUE study to include China sites. That study is evaluating ripretinib vs. approved drug Sutent sunitinib...
BioCentury | May 10, 2019
Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

...II CABOSUN trial of cabozantinib to treat first-line renal cell carcinoma improved PFS vs. Sutent sunitinib...
...was soon followed by a PFS benefit in the Phase II CABOSUN trial vs. Sutent sunitinib...
...from the Phase III CheckMate 9ER trial, which is evaluating Cabometyx plus Opdivo nivolumab vs. Sutent...
BioCentury | Apr 22, 2019
Company News

Keytruda combo gains FDA approval in first-line RCC

...setting. Both the Keytruda and Bavencio combinations with Inlyta led to survival benefits over Sutent sunitinib...
...clinical trials, citing multiple Phase III programs for checkpoint inhibitors in RCC that all used Sutent...
BioCentury | Apr 5, 2019
Product Development

Pazdur on pandemonium: calls for collaboration, competition on PD-1 drugs

...the multiple ongoing Phase III trials in renal cell carcinoma that are all using Sutent sunitinib...
Items per page:
1 - 10 of 401